TOC
Home > People at the DRFZ > Prof. Dr. med. Dr. rer. nat. Ahmed N. Hegazy

Prof. Dr. med. Dr. rer. nat. Ahmed N. Hegazy

Programme Area 4, PA 4 – Translational Rheumatology

Group leader: Inflammatory Mechanisms

Liaison working group with Charité - Gastroenterology, Infectiology and Rheumatology

+49-30-450 514 343

ahmed.hegazy@charite.de

Medizinischen Klinik mit Schwerpunkt Gastroenterologie, Infektiologie und Rheumatologie
Charité – Universitätsmedizin Berlin
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin

E-mail: ahmed.hegazy@drfz.de
Charite Homepage: https://gastro.charite.de

Scientific Background

Since 2023
Tenured W2 Professor of Translational Gastroenterology, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin

2018 – 2023
Lichtenberg Professor of Translational Gastroenterology, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin

Since 2018
Principal Investigator, German Rheumatism Research Centre Berlin

Since 2017
Internal Medicine Resident, Department of Gastroenterology, Infectiology and Rheumatology, Charité – Universitätsmedizin Berlin, Germany (Headed by Prof. Britta Siegmund); Qualification for “Facharzt Innere Medizin”

2012 – 2017
Postdoctoral Researcher, Translational Gastroenterology Unit, Kennedy Institute of Rheumatology, University of Oxford, United Kingdom (Mentor: Prof. Fiona Powrie)

2012 – 2012
Research Associate, Experimental Immunology and Osteoarthritis Research, Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin (Headed by Prof. Max Löhning)

2010 – 2012
Internal Medicine Resident, Department of Gastroenterology, Charité – Universitätsmedizin Berlin, Germany (Headed by Prof. Martin Zeitz)

2006 – 2007
Research Residence as part of Ph.D. training at the Institute of Experimental Immunology, University Hospital Zürich, Switzerland (Mentors: Prof. Zinkernagel and Prof. H. Hengartner)

2012
Doctor of Philosophy in Immunology (Dr. rer. nat.), “summa cum laude”; Institute of Biology, Humboldt University of Berlin, Germany; Dissertation: „Stability and Plasticity of T Helper Type 1 and Type 2 Differentiation Programs“

2010
Doctor of Medicine (Dr. med.), “summa cum laude”, Department of Pediatric Hematology and Oncology, Hannover Medical School (MHH), Germany; Dissertation: „Role of CD4+ T Cell-Mediated Anti-Tumor Immunity in a BCR-ABL+ Murine Model of Acute Lymphoblastic Leukemia“

2007
Approbation, License to Practice Medicine, Germany

2005
Staatsexamen, Hannover Medical School, Germany

1996 – 2004
Bachelor of Medicine, Hannover Medical School (MHH), Germany and Faculty of Medicine, Cairo University, Egypt

Deutsche Gesellschaft für Immunologie; British Society for Immunology; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten; European Crohn’s & Colitis Organisation; Arab-German Young Academy of sciences and humanities

2023
Successful evaluation of the Lichtenberg Professorship, Volkswagen Foundation

2022
Award of ERC Starting Grant 2022 “iMOTIONS” – European Commission

2018
Fellow of the BIH Clinician Scientist Excellence Programme, BIH

2017
Robert-Koch Postdoctoral Prize in Immunology, RKI Foundation

2017
Election to the Arab-German Young Academy of Sciences and Humanities, Berlin – Brandenburg Academy of Sciences and Humanities

2017
Fellow of the BIH Junior Clinician Scientist Programme, Berlin Institute of Health (BIH)

2017
Lichtenberg Professorship, Volkswagen Foundation

2014 – 2016
Marie Curie Actions-Intra-European Fellowship for career development, European Commission

2013 – 2014
EMBO Long-Term Fellowship for postdoctoral research

2012
Feodor Lynen Research Fellowship, Alexander von Humboldt Foundation

2011
Dissertation Award for Tumour Research, Hannover Medical School

TOP PUBLICATIONS

The IL-22–oncostatin M axis promotes intestinal inflammation and tumorigenesis Cineus R, Luo Y, Saliutina M, Manna S, Cancino CA, Velasco Blázquez L, Wang L, Bösel D, Abdelrahman A, Klementowicz JE, Scherl A, Hainbuch S, Bréart B, Kwon G, Konopka A, Guerra GM, von Coburg E, Gerbeth L, Roels J, Heinrich F, Müller N, Durek P, Deigendesch N, Ziai J, Hung J, Conrad T; TRR241 IBDome Consortium; Kühl AA, Wirtz S, Löhning M, Keir M, Diefenbach A, Mashreghi MF, Siegmund B, Schumann M, Romagnani C, West NR, Hegazy AN. The IL-22-oncostatin M axis promotes intestinal inflammation and tumorigenesis. Nat Immunol. 2025 May 30. doi: 10.1038/s41590-025-02149-z. Epub ahead of print. PMID: 40447860.
Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4+ T cells as predictors for response to integrin α4β7-blocking therapy in patients with inflammatory bowel disease Horn, V., Cancino, C., Steinheuer, L., Fritz, K., Obermeyer-Wasserscheid, B., Bösel, D., Burns, M., Schulz, A., Mantzivi, E., Sonnenberg, E., Weidinger, C., Siegmund, B., Mei, H. E., Thurley, K., & Hegazy, A. N. (2023). Multi-omic approach identifies circulating T cell characteristics associated with response to anti-integrin biologic therapy in inflammatory bowel diseases. *Biorxiv*. https://doi.org/10.1101/2023.10.01.560386
Plasticity and lineage commitment of individual Th1 cells are determined by stable T-bet expression quantities. Sci Adv. 2024 Jun 7;10(23) Hegazy, A.N., Peine, C., Niesen, D., Panse, I., Vainshtein, Y., Kommer, C., Zhang, Q, Brunner, T.M., Peine, M., Fröhlich, A., Ishaque, N., Marek, R.M., Zhu, J., Höfer, T., Löhning, M. (2024). Plasticity and lineage commitment of individual Th1 cells are determined by stable T-bet expression quantities. Sci Adv. 2024 Jun 7;10(23):eadk2693
Circulating and Tissue-Resident CD4+ T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation Hegazy* , A. N., West*, N. R., et al., (2017). Circulating and Tissue-Resident CD4+ T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation. Gastroenterology 153, 1320-1337.e16.
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease West* , N. R., Hegazy* , A. N., et al., (2017). Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23, 579–589.
Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage Bhattacharya* , A., Hegazy *, A.N., et al., (2015). Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity 43, 974–986.
Interferons Direct Th2 Cell Reprogramming to Generate a Stable GATA-3+T-bet+ Cell Subset with Combined Th2 and Th1 Cell Functions Hegazy, A.N., et al., (2010). Interferons Direct Th2 Cell Reprogramming to Generate a Stable GATA-3+T-bet+ Cell Subset with Combined Th2 and Th1 Cell Functions. Immunity 32, 116–128.

Inflammatory Mechanisms

Hegazy lab
learn more

News

Go to end of slider
Show more

Projects

Go to end of slider